On September 27, 2018 Janssen Biotech, Inc. (Janssen) reported its decision not to continue the collaboration and license agreement with Geron Corporation for imetelstat (Press release, Johnson & Johnson, SEP 27, 2018, View Source [SID1234529885]). The decision not to continue the collaboration is the result of a strategic portfolio evaluation and prioritization of assets within the robust Janssen portfolio. Janssen will work with Geron to transition the imetelstat program back to the company. Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including treatment and follow-up. The imetelstat collaboration began on November 13, 2014 when Janssen entered into an exclusive worldwide collaboration and license agreement with Geron to develop and commercialize imetelstat in oncology, including hematologic myeloid malignancies. About the Janssen Pharmaceutical Companies of Johnson & Johnson At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Media Inquiries: Brian Kenney Phone: 1-215-620-0111 Satu Kaarina Glawe Phone: +49 172 294 6264 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical Inquiries: 1-800-526-7736 View original content:View Source SOURCE Janssen Biotech, Inc. News Provided by Acquire Media

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 26, 2018 Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, reported that Ms. Kyri Van Hoose, Head of Finance, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York City (Press release, Avelas Biosciences, SEP 26, 2018, View Source [SID1234530225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 26, 2018 Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins, reported the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share, for aggregate gross proceeds of approximately $120 million, before deducting underwriting discounts and commissions and estimated offering expenses (Press release, Arvinas, SEP 26, 2018, View Source [SID1234531302]). In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to 1,125,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Arvinas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The common stock is expected to begin trading on the Nasdaq Global Select Market on September 27, 2018 under the symbol "ARVN." The offering is expected to close on October 1, 2018, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Citigroup and Piper Jaffray & Co., are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on September 26, 2018. The offering is being made only by means of a prospectus forming part of the registration statement relating to these shares. Copies of the prospectus, when available, may be obtained by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 800-831-9146; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at 800-747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 26, 2018 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology, Oct. 3, 2018, at 10:30 am ET (Press release, Five Prime Therapeutics, SEP 26, 2018, View Source [SID1234529605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On September 26, 2018 Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders, reported the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share (Press release, Sutro Biopharma, SEP 26, 2018, View Source [SID1234529637]). All of the shares are being offered by Sutro. The shares are expected to begin trading on The Nasdaq Global Market on September 27, 2018 under the symbol "STRO." The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro, are expected to be approximately $85.0 million. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 850,050 shares of common stock.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Piper Jaffray are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-managers.

In addition to the shares sold in the public offering, Sutro announced the concurrent sale of additional shares of common stock at the initial offering price, for gross proceeds of approximately $10.0 million, in a private placement to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The sale of these shares will not be registered under the Securities Act of 1933, as amended.

The closing of the initial public offering is not conditioned upon the closing of the concurrent private placement.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on September 26, 2018. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (631) 274-2806; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.